<--- Back to Details
First PageDocument Content
Chemistry / Medicine / Diabetes / Dipeptidyl peptidase-4 inhibitors / Amides / Glucagon-like peptide-1 / Anti-diabetic medication / Incretin / Glucose tolerance test / Endocrine system / Anti-diabetic drugs / Peptide hormones
Date: 2013-08-30 08:47:18
Chemistry
Medicine
Diabetes
Dipeptidyl peptidase-4 inhibitors
Amides
Glucagon-like peptide-1
Anti-diabetic medication
Incretin
Glucose tolerance test
Endocrine system
Anti-diabetic drugs
Peptide hormones

Add to Reading List

Source URL: professional.diabetes.org

Download Document from Source Website

File Size: 233,28 KB

Share Document on Facebook

Similar Documents

Dipeptidyl peptidase-4 inhibitors / Eli Lilly and Company / Amides / Anti-diabetic drugs / Peptide hormones / Exenatide / Anti-diabetic medication / Sitagliptin / Saxagliptin / Metformin / Glucagon-like peptide-1 agonist / Sulfonylurea

Official Newsletter of the Utah Poison Control Center 2010 • VOLUME 12 • ISSUE 4 T O D A Y NEW DRUGS FOR TREATMENT OF DIABETES

DocID: 1oY1K - View Document

Biology / Peptide hormones / Anti-diabetic drugs / Eli Lilly and Company / Pancreatic hormones / Glucagon-like peptide-1 / Glucagon / Anti-diabetic medication / Incretin / Endocrine system / Diabetes / Medicine

exploring the role of glucagon in glucose homeostasis exploring the role of glucagon in glucose homeostasis

DocID: 1fV20 - View Document

Medicine / Gastroenterology / Diabetes / Eli Lilly and Company / Clinical research / European Medicines Agency / Anti-diabetic medication / Exenatide / Glucagon-like peptide-1 / Anti-diabetic drugs / Peptide hormones / Endocrine system

Lyxumia - INN, lixisenatide

DocID: 1aV61 - View Document

Diabetes / Nutrition / Peptide hormones / Diets / Anti-diabetic drugs / Blood sugar / Fasting / Dietary fiber / Glucagon-like peptide-1 / Medicine / Health / Biology

Research Effects of indigestible carbohydrates in barley on glucose metabolism, appetite and voluntary food intake over 16 h in healthy adults

DocID: 19WUB - View Document

Anatomy / Biology / Diabetes / Anorectics / Eli Lilly and Company / Exenatide / Monoclonal antibodies / Monoclonal antibody therapy / Glucagon-like peptide-1 / Anti-diabetic drugs / Immunology / Medicine

FOR IMMEDIATE RELEASE INTARCIA AND NUMAB SIGN MULTI-ASSET COLLABORATION TO DEVELOP ONCEYEARLY THERAPIES IN DIABETES, OBESITY, AND AUTOIMMUNE INDICATIONS  Collaboration combines Intarcia’s proprietary delivery tech

DocID: 19uiK - View Document